Logo Image
Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Keyan Salari, MD, PhD

Advertisement

Articles by Keyan Salari, MD, PhD

The UroOnc Minute: Perioperative Treatment for High-Risk Localized Prostate Cancer, With Keyan Salari, MD, PhD

ByAdam B. Weiner, MD,Keyan Salari, MD, PhD
June 26th 2026

In this episode of The UroOnc Minute, Adam B. Weiner, MD, is joined by Keyan Salari, MD, PhD, to examine the results of the PROTEUS trial and their implications for managing high-risk localized prostate cancer.

Advertisement

Latest Updated Articles

  • The UroOnc Minute: Perioperative Treatment for High-Risk Localized Prostate Cancer, With Keyan Salari, MD, PhD
    The UroOnc Minute: Perioperative Treatment for High-Risk Localized Prostate Cancer, With Keyan Salari, MD, PhD

    June 26th 2026



Advertisement
Advertisement

Trending on Urology Times

1

FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC

2

Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence

3

Matching mCSPC treatment to the patient, not just the trial data

4

Urocross Expander System enters US commercial use for symptomatic BPH

5

Variation in PSMA PET Adoption for Prostate Cancer Care

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us